JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boldt, J.
Right arrow Articles by Isgro, F.
Related Collections
Right arrow Surgery
Right arrow Heart
Right arrow Pharmacology

Anesth Analg 2004;99:1009-1017
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000132969.88550.96


CARDIOVASCULAR ANESTHESIA

The Prophylactic Use of the ß-Blocker Esmolol in Combination with Phosphodiesterase III Inhibitor Enoximone in Elderly Cardiac Surgery Patients

Joachim Boldt, MD PhD*, Christian Brosch, MD*, Andreas Lehmann, MD*, Stephan Suttner, MD*, and Frank Isgro, MD{dagger}

Departments of *Anesthesiology and Intensive Care Medicine and {dagger}Cardiac Surgery, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany

Address correspondence and reprint requests to Prof. Dr. Joachim Boldt, Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, Ludwigshafen, Germany. Address e-mail to boldtj{at}gmx.net

We assessed the influence of the prophylactic use of a combination of the IV ß-adrenergic blocker, esmolol, and the phosphodiesterase III inhibitor, enoximone, on postbypass hemodynamic status, inflammation, and endothelial and organ function in a prospective, randomized, placebo-controlled study in 42 patients aged >65 yr undergoing aortocoronary bypass grafting. In 21 patients, esmolol (aim: heart rate <70 bpm) plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 µg · kg–1 · min–1) was started after induction of anesthesia and continued until the morning of the first postoperative day; another 21 patients received saline solution as placebo. Hemodynamics, splanchnic perfusion (gastric-arterial CO2 gap), liver function (glutathione transferase-{alpha} plasma levels), renal function (creatinine clearance, urine concentrations of N-acetyl-ß-D-glucosaminidase), myocardial ischemia (creatine-kinase MB and troponin T plasma levels), inflammation (elastase, interleukin-6 and -8 plasma levels), and endothelial integrity (adhesion molecules plasma levels) were assessed at baseline, before and after cardiopulmonary bypass (CPB), and in the intensive care unit until the first postoperative day. Catecholamine requirements were significantly less in the treated than in the nontreated patients. Heart rate was significantly slower, cardiac index was higher, and gastric-arterial CO2 gap was significantly lower in the treatment group. Troponin T, ß-N-acetyl-ß-D-glucosaminidase, glutathione transferase-{alpha}, and soluble adhesion molecules increased significantly in the untreated control, but remained almost normal in the esmolol+enoximone patients. Inflammatory responses (elastase/interleukins) were attenuated by esmolol+enoximone. We conclude that, in comparison to an untreated control, the prophylactic use of a combination of esmolol and enoximone in elderly patients undergoing cardiac surgery with cardiopulmonary bypass resulted in overall beneficial effects on postbypass hemodynamic status, organ function, inflammatory response, and endothelial integrity.

IMPLICATIONS: Compared with an untreated control group, the prophylactic use of an IV combination of the ß-adrenergic blocker, esmolol, and the phosphodiesterase III inhibitor, enoximone, in elderly patients undergoing cardiac surgery with cardiopulmonary bypass resulted in beneficial effects on postbypass hemodynamic status, splanchnic perfusion, organ function, as well as inflammatory response and endothelial integrity.




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
S. J. Laing, A. R. Jackson, R. Walters, E. Lloyd-Jones, M. Whitham, N. Maassen, and N. P. Walsh
Human blood neutrophil responses to prolonged exercise with and without a thermal clamp
J Appl Physiol, January 1, 2008; 104(1): 20 - 26.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. E. A. Burns, M. W. A. Chu, R. J. Novick, S. A. Fox, K. Gallo, C. M. Martin, L. W. Stitt, A. P. Heidenheim, M. L. Myers, and L. Moist
Perioperative N-acetylcysteine to Prevent Renal Dysfunction in High-Risk Patients Undergoing CABG Surgery: A Randomized Controlled Trial
JAMA, July 20, 2005; 294(3): 342 - 350.
[Abstract] [Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2004 by the International Anesthesia Research Society.